Pr Eric E. GabisonCornea and ocular surface · Paris
FR EN
HomeCorneal wound healing › Summary
Course contents ▾
  1. Introduction & aims
  2. Epithelial healing
  3. Stromal healing
  4. Delayed healing & PED
  5. Corneal fibrosis (haze)
  6. Ulceration & CD147/MMP
  7. Angiogenic privilege
  8. Corneal neovascularization
  9. Summary & key points
  10. Summary table
  11. References
Chapter 4 of 4

Summary

Summary & key points

  • Repairing the cornea means a constant dialogue between epithelium and stroma, shaped by the tears and immune cells.
  • As long as this balance holds, the cornea keeps its clarity and refractive power — the ultimate goal of any healing.
  • The epithelial basement membrane is the true switch: its regeneration ends the TGF-β/PDGF inflow and hence fibrosis.
  • An epithelial wound closed within a few days heals without a trace; if it lingers, it slips into delayed healing, fibrosis or melting.
  • EMMPRIN/CD147 is a hub: it induces MMPs (stromal melting) and regulates the epithelial barrier via occludin (dry eye) — a therapeutic target.
  • Neovascularization betrays a breach of the angiogenic (and lymphangiogenic) privilege, costing transparency and transplant immunity.
  • Removing aggravating factors early — toxic drops, dryness, exposure, loss of sensation — remains the highest-yield step.
Take-home

The time to re-epithelialization and the state of the basement membrane determine the outcome: rapid closure shuts the growth-factor window and allows transparent repair; delay directs healing toward fibrosis, melting or neovascularization.

Summary table

Regenerative vs pathological healing
ParameterRegenerative healingPathological healing
Re-epithelializationFast (< ~8 d) favourableDelayed / PED (> 1 wk) at risk
Epithelial basement membraneReforms then matures (~6 wk)Immature / persistently absent
Barrier (occludin)Tight junctions intactOccludin cleavage (EMMPRIN↑, MMP-9↑)
Keratocytes → myofibroblastsProgenitor apoptosis before maturityPersistent mature myofibroblasts (α-SMA)
Stromal matrixReorganized, orderedDisorganized (collagen III, tenascin, GAG)
MMP / TIMP balanceControlled balancedCollagenolysis (CD147↑, TIMP↓) unbalanced
VesselsAvascular cornea (privilege kept)Neovascularization (hem- & lymph-)
TransparencyPreservedHaze / opacity, loss of immune privilege

Synthetic teaching landmarks; time thresholds are indicative and depend on the background.

References & further reading

Original teaching synthesis. The detailed reference text appears in the chapter “Cicatrisation cornéenne” (M. Cavaillé, C. Tolosa Leal, É. Gabison), in La Cornée en 3D: dégénérescences, dystrophies et déformations, Elsevier Masson, 2025.

Team's own work

  1. Gabison EE, Mourah S, Steinfels E, et al. (Menashi S). Differential expression of EMMPRIN (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and MMP induction. Am J Pathol 2005;166(1):209–19. link.
  2. Gabison EE, Huet E, Baudouin C, Menashi S. Direct epithelial–stromal interaction in corneal wound healing: role of EMMPRIN/CD147 in MMPs induction and beyond. Prog Retin Eye Res 2009;28(1):19–33. link.
  3. Huet E, Vallée B, Delbé J, et al. (Gabison EE). EMMPRIN modulates epithelial barrier function through a MMP-mediated occludin cleavage: implications in dry eye disease. Am J Pathol 2011;179(3):1278–86. link.
  4. Catanese M, Popovici C, Proust H, et al. (Gabison EE). FISH on corneal impression cytology specimens (CICS): study of epithelial cell survival after keratoplasty. Invest Ophthalmol Vis Sci 2011;52(3):1009–13. link.
  5. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001;12(4):242–249. link.
  6. Gabison E, … Azar DT. Anti-angiogenic role of angiostatin during corneal wound healing. Exp Eye Res 2004;78(3):579–589. link.

Key literature

  1. Ljubimov AV, Saghizadeh M. Progress in corneal wound healing. Prog Retin Eye Res 2015;49:17–45.
  2. Wilson SE. Corneal wound healing. Exp Eye Res 2020;197:108089.
  3. Wilson SE, Torricelli AAM, Marino GK. Corneal epithelial basement membrane: structure, function and regeneration. Exp Eye Res 2020;194:108002.
  4. Kamil S, Mohan RR. Corneal stromal wound healing: major regulators and therapeutic targets. Ocul Surf 2021;19:290–306.
  5. Fini ME. Keratocyte and fibroblast phenotypes in the repairing cornea. Prog Retin Eye Res 1999;18:529–51.
  6. Wilson SE, Chaurasia SS, Medeiros FW. Apoptosis in the corneal wound healing response. Exp Eye Res 2007;85:305–11.
  7. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing. Trans Am Ophthalmol Soc 2006;104:264–302.
  8. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443:993–7.
  9. Cursiefen C, Chen L, Dana MR, Streilein JW. Corneal lymphangiogenesis: evidence, mechanisms and implications for transplant immunology. Cornea 2003;22:273–81.
  10. Dua HS, Gomes JA, Singh A. Corneal epithelial wound healing. Br J Ophthalmol 1994;78:401–8.
  11. Han KY, Tran JA, Chang JH, et al. Corneal epithelial cell-derived exosomes in wound healing and neovascularization. Sci Rep 2017;7:40548.
  12. Mannis MJ, Holland EJ (eds). Cornea, 5th ed. Elsevier, 2021.
  13. Wilson SE. Analysis of keratocyte apoptosis, keratocyte proliferation and myofibroblast transformation after PRK and LASIK. Trans Am Ophthalmol Soc 2002;100:411–33.
  14. Wilson SE. Biology of keratorefractive surgery — PRK, PTK, LASIK, SMILE, inlays and other refractive procedures. Exp Eye Res 2020;198:108136.
  15. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium‑derived factor: a potent inhibitor of angiogenesis. Science 1999;285(5425):245–248.
  16. Kubo H, Cao R, Brakenhielm E, et al. Blockade of VEGFR‑3 signaling inhibits FGF‑2‑induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci USA 2002;99(13):8868–8873.
  17. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001;414(6863):550–554.
Glossary of abbreviations used in this course

Scientific abbreviations and acronyms used throughout the 10 pages of this course, listed alphabetically.

95% CI
95% confidence interval
AAV
adeno-associated virus (gene-therapy viral vector)
ABCG2
ABCG2 transporter, a limbal stem-cell marker
AMT
amniotic membrane transplantation
anti-VEGF
anti-angiogenic treatment targeting VEGF
ASC
inflammasome adaptor protein (Apoptosis-associated Speck-like protein containing a CARD)
BrdU
bromodeoxyuridine, a cell-proliferation marker
CCL2
CCL2 chemokine, synonym of MCP-1; recruits circulating monocytes
CCR2
receptor for CCL2; marker of newly recruited monocytes/macrophages
CD147
cluster of differentiation 147; synonym of EMMPRIN and basigin
CD163
M2 macrophage marker; scavenger receptor for haemoglobin-haptoglobin
CD206
mannose receptor; marker of M2 polarization
CD74
cell-surface receptor for MIF
CDVA
corrected distance visual acuity
CGRP
calcitonin gene-related peptide
CTGF
connective tissue growth factor
CX3CL1
fractalkine, a chemokine involved in monocyte/macrophage recruitment
CXCR2/CXCR4
chemokine receptors, also receptors for MIF
DAMP
damage-associated molecular pattern
DESI
direct epithelial–stromal interaction
EGF
epidermal growth factor
EGFR
epidermal growth factor receptor
EMMPRIN
extracellular matrix metalloproteinase inducer; synonym of CD147
ETDRS
reference visual-acuity scale used in clinical research (Early Treatment Diabetic Retinopathy Study)
FasL
Fas ligand, an apoptosis-inducing protein
FISH
fluorescence in situ hybridisation
GAG
glycosaminoglycan(s)
GM-CSF
granulocyte-macrophage colony-stimulating factor
GVHD
graft-versus-host disease
HGF
hepatocyte growth factor
HIF-3α
hypoxia-inducible factor, 3-alpha subunit
HMGB1
high mobility group box 1, an alarmin released by injured cells (DAMP)
IFN-γ
interferon gamma
IGF-1
insulin-like growth factor 1
IL-1
interleukin-1
iNOS
inducible nitric oxide synthase
IPAS
inhibitory PAS domain protein
KGF
keratinocyte growth factor
LASIK
laser-assisted in situ keratomileusis
LogMAR
logarithmic visual-acuity scale
LOX
lysyl oxidase, a collagen cross-linking enzyme
LPS
bacterial lipopolysaccharide
M1
classically activated macrophage, pro-inflammatory profile
M2
alternatively activated macrophage, pro-resolving/reparative profile (subtypes M2a-M2d, M2eff)
MEN2B
multiple endocrine neoplasia type 2B
MerTK
receptor tyrosine kinase involved in efferocytosis
MIF
macrophage migration inhibitory factor
MRI
magnetic resonance imaging
NGF
nerve growth factor
NK
neurotrophic keratitis
NLRP3
NLRP3 inflammasome (NOD-, LRP- and pyrin domain-containing protein 3)
NO
nitric oxide
NSAID
nonsteroidal anti-inflammatory drug
PACAP
pituitary adenylate cyclase-activating polypeptide
PAF
platelet-activating factor
PAMP
pathogen-associated molecular pattern
PDGF
platelet-derived growth factor
PED
persistent epithelial defect
PEDF
pigment epithelium-derived factor
PGE₂
prostaglandin E2
PRK
photorefractive keratectomy (laser surface ablation)
pro-NGF
precursor form of NGF
RGTA
matrix-therapy ReGeneraTing Agent, e.g. Cacicol
rhNGF
recombinant human NGF (cenegermin)
ROS
reactive oxygen species
Smad
signalling proteins of the TGF-β pathway
SPK
superficial punctate keratitis
sVEGFR-1
soluble form of VEGF receptor-1 (= sFlt-1)
sVEGFR-3
soluble form of VEGF receptor-3
TGF-β
transforming growth factor beta
TIMP
tissue inhibitor of metalloproteinases
TLR
Toll-like receptor
TNF-α
tumour necrosis factor alpha
TRPV4
transient receptor potential vanilloid 4, a mechanosensitive ion channel
uPA
urokinase-type plasminogen activator
V1
ophthalmic branch of the trigeminal nerve
VEGF
vascular endothelial growth factor
VEGF-C
lymphangiogenic isoform of VEGF
VIP
vasoactive intestinal peptide
YAP/TAZ
Hippo pathway effectors, mechanosensors of matrix stiffness
α-SMA
alpha-smooth muscle actin, a myofibroblast marker